{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:29:51Z","timestamp":1784204991723,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Castleman disease (CD), classified as unicentric CD (UCD) or multicentric CD (MCD), is a rare non-neoplastic lymphoproliferative disorder of unknown origin. Owing to its rarity, the clinical characteristics, therapeutic modalities, treatment outcomes, and prognostic factors related to UCD or MCD are not well defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We retrospectively analyzed 88 patients with CD, including those with hyaline-vascular, plasma-cell, mixed type, hypervascular, and plasmablastic subtypes, for presenting symptoms, physical, laboratory, and radiologic findings, and treatment response in the Korean population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median patient age was 44 years (range: 18\u201384 years) with slight predominance of women (53.4%). UCD and MCD accounted for 38.6% (n=34) and 61.4% (n=54) of cases, respectively. Histopathologically, UCD patients were classified as 88.2% (n=30) hyaline-vascular and 11.8% (n=4) plasma cell types, whereas MCD patients were classified as 27.8% (n=15) hypervascular, 61.1% (n=33) plasma cell, 7.4% (n=4) mixed, and 3.7% (n=2) plasmablastic types. Twelve (13.6%) patients exhibited a poor performance status with an Eastern Cooperative Oncology Group score of 2. The most common presenting symptom was sustained fever, followed by fatigue, anorexia, peripheral edema, and weight loss. Furthermore, splenomegaly, pleural effusion, and ascites were observed to be associated with CD. Surgical resection and siltuximab were the preferred treatment modalities for UCD and MCD, respectively, with favorable symptomatic, laboratory, and radiologic outcomes and safety profiles. The overall survival was 90.2%, with no significant difference between the UCD and MCD groups (p=0.073), but progression-free survival was significantly poorer in the MCD group (p=0.001). Age \u226560 years and splenomegaly significantly affected the overall and progression-free survival rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with UCD had favorable outcomes with surgical resection of a solitary mass, whereas in patients with MCD, old age and splenomegaly were identified as independent prognostic factors. Further well-designed prospective studies under advancing knowledge of the pathophysiology of MCD are warranted to establish suitable guidelines for the discontinuation or prolonging infusion intervals of siltuximab and treatment modalities for HHV-8 positive MCD patients or patients with siltuximab failure.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.974770","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T10:13:13Z","timestamp":1659694393000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-term treatment outcome of Castleman\u2019s disease: A real-world experience"],"prefix":"10.3389","volume":"12","author":[{"given":"Gi-June","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Woo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Hun","family":"Kwag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hyuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Yeop","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::aid-cncr2820090430>3.0.co;2-4","article-title":"Localized mediastinal lymphnode hyperplasia resembling thymoma","volume":"9","author":"Castleman","year":"1956","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8\u2013negative\/idiopathic multicentric castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318249dcdc","article-title":"Surgery in castleman\u2019s disease: a systematic review of 404 published cases","volume":"255","author":"Talat","year":"2012","journal-title":"Ann Surg"},{"key":"B4","article-title":"Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy","volume":"8","author":"van Rhee","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bjh.12717","article-title":"Clinical epidemiology and treatment patterns of patients with multicentric castleman disease: results from two US treatment centres","volume":"165","author":"Robinson","year":"2014","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3960\/jslrt.53.69","article-title":"Clinical features and treatment of multicentric castleman\u2019s disease: a retrospective study of 21 Japanese patients at a single institute","volume":"53","author":"Kawabata","year":"2013","journal-title":"J Clin Exp Hematop"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1704983","article-title":"Clinicopathologic characteristics of 342 patients with multicentric castleman disease in Japan","volume":"30","author":"Murakami","year":"2020","journal-title":"Mod Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15019","article-title":"The full spectrum of castleman disease: 273 patients studied over 20 years","volume":"180","author":"Oksenhendler","year":"2018","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2377","article-title":"Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for castleman\u2019s disease","volume":"28","author":"van Rhee","year":"2010","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15921","article-title":"Treatment and outcome of unicentric castleman disease: a retrospective analysis of 71 cases","volume":"186","author":"Boutboul","year":"2019","journal-title":"Br J Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7625","article-title":"A retrospective study of 34 patients with unicentric and multicentric castleman\u2019s disease: experience from a single institution","volume":"15","author":"Jiang","year":"2018","journal-title":"Oncol Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13378","article-title":"Clinical and laboratory characterization of 114 cases of castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor","volume":"169","author":"Dong","year":"2015","journal-title":"Br J Haematol"},{"key":"B15","article-title":"Complete anemia reversal after surgical excision of mesenteric hyaline-vascular unicentric castleman disease","volume":"52","author":"Bejjani","year":"2009","journal-title":"Can J Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010801)92:3<670::aid-cncr1369>3.0.co;2-q","article-title":"Treatment of unicentric and multicentric castleman disease and the role of radiotherapy","volume":"92","author":"Chronowski","year":"2001","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19990201)85:3<706::aid-cncr21>3.0.co;2-7","article-title":"The management of unicentric and multicentric castleman\u2019s disease: a report of 16 cases and a review of the literature","volume":"85","author":"Bowne","year":"1999","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.hoc.2017.09.006","article-title":"Unicentric castleman disease","volume":"32","author":"Wong","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"B19","doi-asserted-by":"publisher","first-page":"A2","DOI":"10.1016\/j.chest.2017.08.032","article-title":"Castleman disease: A clinical and diagnostic dilemma","volume":"152","author":"Gupta","year":"2017","journal-title":"Chest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S60514","article-title":"Update and new approaches in the treatment of castleman disease","volume":"7","author":"Chan","year":"2016","journal-title":"J Blood Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.9.1202","article-title":"A systemic lymphoproliferative disorder with morphologic features of castleman\u2019s disease: clinical findings and clinicopathologic correlations in 15 patients","volume":"3","author":"Frizzera","year":"1985","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/cas.13439","article-title":"Clinical characteristics and outcomes of castleman disease: A multicenter study of 185 Chinese patients","volume":"109","author":"Zhang","year":"2018","journal-title":"Cancer Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0923-2","article-title":"Multicentric castleman\u2019s disease complicated by tumor lysis syndrome","volume":"83","author":"Lee","year":"2004","journal-title":"Ann Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1909","article-title":"Clinical features and outcome in HIV-associated multicentric castleman\u2019s disease","volume":"29","author":"Bower","year":"2011","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.6732","article-title":"Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus-associated multicentric castleman\u2019s disease: ANRS 117 CastlemaB trial","volume":"25","author":"G\u00e9rard","year":"2007","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-848671","article-title":"Novel insights and therapeutic approaches in idiopathic multicentric castleman disease","volume":"132","author":"Fajgenbaum","year":"2018","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02042-3","article-title":"A new approach to the management of COVID-19. antagonists of IL-6: siltuximab","volume":"39","author":"Villaescusa","year":"2022","journal-title":"Adv Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.37201\/req\/045.2021","article-title":"Experience with the use of siltuximab in patients with SARS-CoV-2 infection","volume":"34","author":"Meira","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1356-62","DOI":"10.7150\/ijms.53564","article-title":"Role of IL-6 inhibitor in the treatment of COVID-19-related cytokine release syndrome","volume":"18","author":"Du","year":"2021","journal-title":"Int J Med Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01299-x","article-title":"Siltuximab downregulates interleukin-8 and PENTRAXIN 3 to improve ventilatory status and survival in severe COVID-19","volume":"35","author":"Gritti","year":"2021","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3253","article-title":"Cutaneous disorders associated with castleman\u2019s disease","volume":"99","author":"Kim","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/srep23831","article-title":"Clinical spectrum and survival analysis of 145 cases of HIV-negative castleman\u2019s disease: renal function is an important prognostic factor","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.53.63","article-title":"Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly: A clinical report of five cases","volume":"53","author":"Takai","year":"2013","journal-title":"J Clin Exp Hematop"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25554","article-title":"Is TAFRO syndrome a subtype of idiopathic multicentric castleman disease","volume":"94","author":"Fujimoto","year":"2019","journal-title":"Am J Hematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-545087","article-title":"HHV-8-negative, idiopathic multicentric castleman disease: novel insights into biology, pathogenesis, and therapy","volume":"123","author":"Fajgenbaum","year":"2014","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-1979-1","article-title":"Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version","volume":"103","author":"Masaki","year":"2016","journal-title":"Int J Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04762-6","article-title":"Castleman disease and TAFRO syndrome","volume":"101","author":"Masaki","year":"2022","journal-title":"Ann Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.974770\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T10:13:16Z","timestamp":1659694396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.974770\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":39,"alternative-id":["10.3389\/fonc.2022.974770"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.974770","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"article-number":"974770"}}